Zika virus infection in pregnancy: a protocol for the joint analysis of the prospective cohort studies of the ZIKAlliance, ZikaPLAN and ZIKAction consortia.
Ades, AE;
Brickley, Elizabeth B;
Alexander, Neal;
Brown, David;
Jaenisch, Thomas;
Miranda-Filho, Demócrito de Barros;
Pohl, Moritz;
Rosenberger, Kerstin D;
Soriano-Arandes, Antoni;
Thorne, Claire;
+27 more...Ximenes, Ricardo Arraes de Alencar;
de Araújo, Thalia Velho Barreto;
Avelino-Silva, Vivian I;
Bethencourt Castillo, Sarah Esperanza;
Borja Aburto, Victor Hugo;
Brasil, Patrícia;
Christie, Celia DC;
de Souza, Wayner Vieira;
Gotuzzo H, Jose Eduardo;
Hoen, Bruno;
Koopmans, Marion;
Martelli, Celina Maria Turchi;
Martins Teixeira, Mauro;
Marques, Ernesto TA;
Miranda, Maria Consuelo;
Montarroyos, Ulisses Ramos;
Moreira, Maria Elisabeth;
Morris, J Glenn;
Rockx, Barry;
Saba Villarroel, Paola Mariela;
Soria Segarra, Carmen;
Tami, Adriana;
Turchi, Marília Dalva;
Giaquinto, Carlo;
de Lamballerie, Xavier;
Wilder-Smith, Annelies;
EC Zika Consortia Vertical Transmission Study Group;
(2020)
Zika virus infection in pregnancy: a protocol for the joint analysis of the prospective cohort studies of the ZIKAlliance, ZikaPLAN and ZIKAction consortia.
BMJ OPEN, 10 (12).
e035307-.
ISSN 2044-6055
DOI: https://doi.org/10.1136/bmjopen-2019-035307
Permanent Identifier
Use this Digital Object Identifier when citing or linking to this resource.
INTRODUCTION: Zika virus (ZIKV) infection in pregnancy has been associated with microcephaly and severe neurological damage to the fetus. Our aim is to document the risks of adverse pregnancy and birth outcomes and the prevalence of laboratory markers of congenital infection in deliveries to women experiencing ZIKV infection during pregnancy, using data from European Commission-funded prospective cohort studies in 20 centres in 11 countries across Latin America and the Caribbean. METHODS AND ANALYSIS: We will carry out a centre-by-centre analysis of the risks of adverse pregnancy and birth outcomes, comparing women with confirmed and suspected ZIKV infection in pregnancy to those with no evidence of infection in pregnancy. We will document the proportion of deliveries in which laboratory markers of congenital infection were present. Finally, we will investigate the associations of trimester of maternal infection in pregnancy, presence or absence of maternal symptoms of acute ZIKV infection and previous flavivirus infections with adverse outcomes and with markers of congenital infection. Centre-specific estimates will be pooled using a two-stage approach. ETHICS AND DISSEMINATION: Ethical approval was obtained at each centre. Findings will be presented at international conferences and published in peer-reviewed open access journals and discussed with local public health officials and representatives of the national Ministries of Health, Pan American Health Organization and WHO involved with ZIKV prevention and control activities.
